Resources from the same session
Treatment with pralsetinib (formerly BLU-667), a potent and selective RET inhibitor, provides rapid clearance of ctDNA in patients with RET-altered non-small cell lung cancer (NSCLC) and medullary thyroid cancer (MTC)
Presenter: Dae Ho Lee
Session: Mini Oral session - Developmental and precision medicine
Resources:
Slides
Webcast
Clinical utility of ctDNA genomic alterations (GA) based on ESMO scale for clinical actionability of molecular targets (ESCAT) in advanced NSCLC
Presenter: Laura Mezquita
Session: Mini Oral session - Developmental and precision medicine
Resources:
Slides
Webcast
Durability of response with larotrectinib in adult and pediatric patients with TRK fusion cancer
Presenter: Daniel Shao Weng Tan
Session: Mini Oral session - Developmental and precision medicine
Resources:
Slides
Webcast
Tepotinib in NSCLC patients harboring METex14 skipping: Cohort A of phase II VISION study
Presenter: Niels Reinmuth
Session: Mini Oral session - Developmental and precision medicine
Resources:
Slides
Webcast
NRG1-fusion-driven solid tumours: A case series indicating the therapeutic potential of afatinib
Presenter: Yasushi Goto
Session: Mini Oral session - Developmental and precision medicine
Resources:
Slides
Webcast